Безопасность лечения как критерий выбораингибитора протонной помпы больномугастроэзофагеальной рефлюксной болезнью
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005; 54: 710–7.
2. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Многоцентровое исследование «Эпидемиология Гастроэзофагеальной Рефлюксной болезни в России» (МЭГРЕ): первые итоги. Экспер. и клин. гастроэнтерол. 2009; 6: 4–12.
3. Vakil N, van Zanden SV, Kahrilas P et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol 2006; 101: 1900–20.
4. Van Pinxteren B, Numan ME, Bonis PA et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.
5. Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease-lifestyle advice and medication. Aliment Pharmacol Ther 2004; 20 Suppl. 8: 24–7.
6. Donnellan C, Preston C, Moayyedi P et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Cochrane Review). In: The Cochrane Library 2009 Issue 2. Chichester, UK: John Wiley and Sons, Ltd.
7. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2 (6): 482–93.
8. Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009; 29 Suppl. 2: 3–12.
9. Pace F, Tonini M, Pallotta S et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 2007; 26: 195–204.
10. Исаков В.А. Безопасность ингибиторов протонного насоса при длительном применении. Клин. фармакол. и тер. 2004; 1: 26–32.
11. Бордин Д.С., Машарова А.А., Лазебник Л.Б. Длительная терапия ингибиторами протонной помпы и риск колоректального рака (обзор литературы). Экспер. и клин. гастроэнтерол. 2008; 4: 36–8.
12. Graham DY, Opekun AR, Yamaoka Y et al. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003; 17 (2): 193–200.
13. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (4-е Московское соглашение). Экспер. и клин. гастроэнтерол. 2010; 5: 113–8.
14. Cote´ GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10 (3): 208–14.
15. Sachs G, Shin JM, Vagin O et al. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007; 41 Suppl. 2: S226–42.
16. Лазебник Л.Б., Бордин Д.С., Машарова А.А. и др. Эффективность ланзоптола при гастроэзофагеальной рефлюксной болезни: результаты многоцентрового исследования ЛИДЕР. Экспер. и клин. гастроэнтерол. 2010; 7.
17. Castell DO, Richter JE, Robinson M et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91 (9): 1749–57.
18. Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: ИКЦ «Академкнига», 2001.
19. Moldin IM, Sachs G. Acid related diseases. Biology and treatment. Schnetztop-Verlag GmbH D-Konstanz. 1998; 126–45.
20. Bardou M, Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol 2008; 4: 471–83.
21. Надинская М.Ю. Рабепразол (париет) в лечении гастроэзофагеальной рефлюксной болезни с позиции медицины, основанной на научных доказательствах. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2004; 1: 2–12.
22. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272 (36): 22438–46.
23. Spicer ZClarke LL, Gawenis LR, Shull GE. Colonic H(+)-K(+)-ATPase in K(+) conservation and electrogenic Na(+) absorption during Na(+) restriction. Am J Physiol Gastrointest Liver Physiol 2001; 281 (6): G1369–77.
24. Marteau C, Sastre B, Iconomidis N et al. pH regulation in human gallbladder bile: study in patients with and without gallstones. Hepatology 1990; 11 (6): 997–1002.
25. Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458 (1): 157–68.
26. Bonanno JA. K (+)-H+ exchange, a fundamental cell acidifier in corneal epithelium. Am J Physiol 1991; 260 (3 Pt 1): C618–25.
27. McDonough AA, Youn JH. Role of muscle in regulating extracellular [K+]. Semin Nephrol 2005; 25 (5): 335–42.
28. Zedtwitz-Liebenstein K, Wenisch C, Patruta S et al. Omeprazole treatment diminishes intra– and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118–22.
29. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K+-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21–5.
30. Лапина Т.Л. Безопасность ингибиторов протонной помпы. Клинические перспективы гастроэнтерологии, гепатологии. 2009; 4.
31. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149 (6): 391–8.
32. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769–84.
33. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63 (1): 101–33.
34. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am 2009; 38 (2): 289–303.
35. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180 (7): 713–8.
36. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009; 43 (7): 1266–74.
37. European Medicines Agency, 17 March 2010, EMA/174948/2010; Public statement: Interaction between clopidogrel and proton-pump inhibitors CHMP updates warning for clopidogrel-containing medicines http:// www.ema.europa.eu/ humandocs/PDFs/EPAR/Plavix/17494810en.pdf
2. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Многоцентровое исследование «Эпидемиология Гастроэзофагеальной Рефлюксной болезни в России» (МЭГРЕ): первые итоги. Экспер. и клин. гастроэнтерол. 2009; 6: 4–12.
3. Vakil N, van Zanden SV, Kahrilas P et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol 2006; 101: 1900–20.
4. Van Pinxteren B, Numan ME, Bonis PA et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.
5. Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease-lifestyle advice and medication. Aliment Pharmacol Ther 2004; 20 Suppl. 8: 24–7.
6. Donnellan C, Preston C, Moayyedi P et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Cochrane Review). In: The Cochrane Library 2009 Issue 2. Chichester, UK: John Wiley and Sons, Ltd.
7. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2 (6): 482–93.
8. Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009; 29 Suppl. 2: 3–12.
9. Pace F, Tonini M, Pallotta S et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 2007; 26: 195–204.
10. Исаков В.А. Безопасность ингибиторов протонного насоса при длительном применении. Клин. фармакол. и тер. 2004; 1: 26–32.
11. Бордин Д.С., Машарова А.А., Лазебник Л.Б. Длительная терапия ингибиторами протонной помпы и риск колоректального рака (обзор литературы). Экспер. и клин. гастроэнтерол. 2008; 4: 36–8.
12. Graham DY, Opekun AR, Yamaoka Y et al. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003; 17 (2): 193–200.
13. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (4-е Московское соглашение). Экспер. и клин. гастроэнтерол. 2010; 5: 113–8.
14. Cote´ GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10 (3): 208–14.
15. Sachs G, Shin JM, Vagin O et al. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007; 41 Suppl. 2: S226–42.
16. Лазебник Л.Б., Бордин Д.С., Машарова А.А. и др. Эффективность ланзоптола при гастроэзофагеальной рефлюксной болезни: результаты многоцентрового исследования ЛИДЕР. Экспер. и клин. гастроэнтерол. 2010; 7.
17. Castell DO, Richter JE, Robinson M et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91 (9): 1749–57.
18. Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: ИКЦ «Академкнига», 2001.
19. Moldin IM, Sachs G. Acid related diseases. Biology and treatment. Schnetztop-Verlag GmbH D-Konstanz. 1998; 126–45.
20. Bardou M, Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol 2008; 4: 471–83.
21. Надинская М.Ю. Рабепразол (париет) в лечении гастроэзофагеальной рефлюксной болезни с позиции медицины, основанной на научных доказательствах. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2004; 1: 2–12.
22. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272 (36): 22438–46.
23. Spicer ZClarke LL, Gawenis LR, Shull GE. Colonic H(+)-K(+)-ATPase in K(+) conservation and electrogenic Na(+) absorption during Na(+) restriction. Am J Physiol Gastrointest Liver Physiol 2001; 281 (6): G1369–77.
24. Marteau C, Sastre B, Iconomidis N et al. pH regulation in human gallbladder bile: study in patients with and without gallstones. Hepatology 1990; 11 (6): 997–1002.
25. Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458 (1): 157–68.
26. Bonanno JA. K (+)-H+ exchange, a fundamental cell acidifier in corneal epithelium. Am J Physiol 1991; 260 (3 Pt 1): C618–25.
27. McDonough AA, Youn JH. Role of muscle in regulating extracellular [K+]. Semin Nephrol 2005; 25 (5): 335–42.
28. Zedtwitz-Liebenstein K, Wenisch C, Patruta S et al. Omeprazole treatment diminishes intra– and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118–22.
29. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K+-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21–5.
30. Лапина Т.Л. Безопасность ингибиторов протонной помпы. Клинические перспективы гастроэнтерологии, гепатологии. 2009; 4.
31. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149 (6): 391–8.
32. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769–84.
33. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63 (1): 101–33.
34. Cryer B. Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterol Clin North Am 2009; 38 (2): 289–303.
35. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180 (7): 713–8.
36. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009; 43 (7): 1266–74.
37. European Medicines Agency, 17 March 2010, EMA/174948/2010; Public statement: Interaction between clopidogrel and proton-pump inhibitors CHMP updates warning for clopidogrel-containing medicines http:// www.ema.europa.eu/ humandocs/PDFs/EPAR/Plavix/17494810en.pdf
Авторы
Д.С.Бордин
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.